Zacks Investment Research on MSN
Biogen Inc. (BIIB) tops Q1 earnings and revenue estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.57 per share, beating the Zacks Consensus Estimate of $2.95 per share. This compares to earnings of $3.02 per share a year ago. These figures ...
Biogen Inc.’s first-quarter sales and profit beat expectations, a sign that the company’s Alzheimer’s drug and cost cuts are ...
Biogen Inc (BIIB) reports a robust start to 2026 with increased revenues and strategic advancements, despite competitive challenges.
Hosted on MSN
Analysts estimate Biogen Inc. (BIIB) to report a decline in earnings: What to look out for
Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives ...
Biogen (NASDAQ:BIIB) executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress ...
Biogen Inc. intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing ...
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The ...
Biogen Inc. (NASDAQ:BIIB) on Thursday agreed to acquire Massachusetts-based Alcyone Therapeutics for $85 million. Alcyone will also receive certain milestones payable related to the development and ...
Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was ...
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s ...
Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results